Key result
Anti-HAV total antibody seroprevalence reached levels >90% only in adulthood (>25 years of age), suggesting South Africa is transitioning from high to intermediate HAV endemicity.
Why the study?
South Africa is considered highly endemic for hepatitis A virus despite few recent seroprevalence studies, and WHO recommends childhood vaccination when transitioning from high to intermediate endemicity.
Cross-Sectional (n=520,847)
Yes
HAV seroprevalence data in South Africa indicates a transition from high to intermediate endemicity, supporting the potential integration of HAV vaccination into childhood immunization schedules.
South African HAV seroprevalence may signal transition to intermediate endemicity; leaves open whether childhood vaccination integration is warranted pending prospective confirmation.
INTRODUCTION: South Africa is considered highly endemic for hepatitis A virus (HAV) although few seroprevalence studies have been conducted over the past two decades. The World Health Organization recommends integrating HAV vaccination into national childhood immunization schedules where there is transition from high to intermediate endemicity. As a means of gauging age-specific rates of infection, we report HAV seroprevalence rates among specimens tested for HAV serology within South Africa's public health sector from 2005-2015. MATERIALS AND METHODS: Hepatitis A serology results (Anti-HAV IgM, IgG and total antibody) from 2005-2015 were extracted from South Africa's National Health Laboratory Service's Corporate Data Warehouse (NHLS CDW), the central data repository of all laboratory test-sets within the public health sector. Results were extracted according to test-set, result, date of testing, health facility, name, surname, age, and sex. Anti-HAV IgG results were merged with total antibody results to reflect anti-HAV seroprevalence. Testing volume, positivity rates and age-specific anti-HAV seroprevalence rates by year and geographic distribution are described. RESULTS AND DISCUSSION: A total of 501 083 HAV IgM results were retrieved, of which 16 423 (3.3%) were positive, 484 259 (96.6%) negative and 401 (0.1%) equivocal; and 34 710 HAV total antibody/IgG tests of which 30 675 (88.4%) were positive, 4 020 (11.6%) negative and 15 equivocal. Whereas IgM positivity was highest among the 1-4 year age group (33.5%) and lowest among patients >45 years (<0.5%), total antibody positivity ranged from its lowest level of 52.7% in the 1-4 year age group increasing to levels of >90% only after 25 years of age. CONCLUSION: Anti-HAV total antibody testing within the South African public health sector demonstrates seroprevalence rates reach levels >90% only in adulthood, suggesting South Africa could be in transition from high to intermediate endemicity. Prospective studies with geographically representative sampling are required to confirm these findings and evaluate provincial and urban/rural heterogeneity.
No takes yet. Share an insight, caveat, or question.
Mazanderani et al. (2019) conducted a cross-sectional in Hepatitis A virus (HAV) infection (n=520,847). Age and geographic distribution was evaluated on Anti-HAV total antibody seroprevalence and anti-HAV IgM positivity. Anti-HAV total antibody seroprevalence reached levels >90% only in adulthood (>25 years of age), suggesting South Africa is transitioning from high to intermediate HAV endemicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: